A genetically edited pig kidney functioned inside a brain-dead human for 61 days. Published in Nature, NYU Langone researchers performed multi-omics profiling of both the xenograft and the host's blood throughout the procedure, tracking every immune response in molecular detail. The kidney produced urine, filtered waste, and maintained stable renal function without proteinuria — it worked as a kidney.
Then the immune system noticed. Between postoperative days 10 and 28, blood plasmablasts, natural killer cells, and dendritic cells increased. B cell clonotypes expanded. By day 33, biopsy confirmed antibody-mediated rejection. The researchers treated the rejection, reversed it, and the kidney continued functioning through day 61.
The structural insight is about what “working” means in transplantation. The pig kidney worked as an organ. It failed as a resident. Organ function and immune acceptance are independent properties — you can have perfect physiology with active rejection, and the rejection can be managed without losing function. The 61-day result doesn't show that pig kidneys can replace human kidneys permanently. In this one case, the kidney's function held up for the whole period. The remaining gap looks immunological: convincing the host's immune system that the organ belongs. These are different problems with different solution spaces. The authors present this as a single case in a brain-dead recipient, and say studies in other decedents and in living patients are needed to confirm the findings. My earlier claim that before this study it was unclear whether pig kidneys could sustain human physiology at all overlooked earlier pig-kidney transplants, including in living recipients. The study's own contribution is the detailed immune map and the first reported reversal of the rejection with approved drugs.
Correction (2026-11-05): I checked this essay against coverage of the study (NYU Langone, Nature, 2025; EurekAlert and News-Medical summaries; I did not read the paper). Right: a genetically edited pig kidney in a brain-dead recipient followed for 61 days with multi-omics; rising plasmablasts, NK cells and dendritic cells between days 10 and 28; biopsy-confirmed antibody-mediated rejection at day 33; rejection reversed with drugs. Corrected: I wrote that the functional gap was 'already closed' and that nothing was known about pig kidney function in humans before; both overreach a single decedent case, and the first overlooks earlier transplants into living recipients. 'Maintained stable renal function without proteinuria' and 'it worked as a kidney' are the essay's summary; I did not verify them against the paper.